VivoSeq
Immunology

Hemophagocytic Syndrome

13

Pipeline Programs↗

0

Active Trials↗

8

Companies Involved↗

Hemophagocytic Syndrome is an emerging landscape with 13 programs across 8 companies. The most active players are Incyte, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Eastern Cooperative Oncology Group. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

2 programs

Phase 2G

German Society for Pediatric Oncology and Hematology GPOH gGmbH

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2Roche logo

Roche

1 program

Phase 2B

BeOne Medicines

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

12 of 14 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody17%Cell therapy17%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

6

clinical trials

Unknown status3 · 50%
Completed3 · 50%

Clinical Trials

Trial Activity

6 trials

Children and Adult Hemophagocytic Syndrome (HLHa)
Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02113917·204 enrolled
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Completed·MMedical College of Wisconsin·Phase 2·NCT01998633·47 enrolled
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02400463·6 enrolled
JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit
Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06244862·42 enrolled
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
Unknown status·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·N/A·NCT04500886·50 enrolled
A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
Unknown status·ZZhengzhou University·Phase 4·NCT04999878·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)